or Try an Advanced Search...

    Technical Analysis for IMVT - Immunovant, Inc.

    Grade Last Price % Change Price Change
    D 29.54 2.21% 0.64
    IMVT closed down 0.62 percent on Wednesday, September 18, 2024, on 79 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical IMVT trend table...
    Date Alert Name Type % Chg
    Gapped Up Strength 2.21%
    Down 3 Days in a Row Weakness 2.21%
    Oversold Stochastic Weakness 2.21%
    50 DMA Resistance Bearish 1.58%
    Multiple of Ten Bearish Other 1.58%
    Outside Day Range Expansion 1.58%
    Oversold Stochastic Weakness 1.58%
    50 DMA Resistance Bearish 0.37%
    MACD Bearish Centerline Cross Bearish 0.37%
    Stochastic Buy Signal Bullish 0.37%
    Older End-of-Day Signals for IMVT ...

       Recent Intraday Alerts

    Alert Time
    50 DMA Resistance about 5 hours ago
    10 DMA Resistance about 5 hours ago
    60 Minute Opening Range Breakout about 6 hours ago
    Rose Above 50 DMA about 6 hours ago
    Rose Above Previous Day's High about 6 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    IMVT Chart by TradingView
    Basic chart:

    Profile

    Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It is developing IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Immune System Eye Autoimmune Disease Antibodies Monoclonal Antibodies Monoclonal Antibody Anemia Thyroid Eye Diseases Treatment Of Autoimmune Disease Myasthenia Gravis Transfusion Medicine Myasthenia Thyroid Eye Disease Acquired Hemolytic Anemia Treatment Of Myasthenia Gravis

    Is IMVT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 9 Immunovant stock falls 8% amid Graves' disease program update
    Sep 9 What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
    Sep 9 Immunovant touts positive Phase II batoclimab data as IMVT-1402 also progresses
    Sep 9 Top 2 Health Care Stocks That May Collapse This Quarter
    Sep 9 IMVT Stock Up on Upbeat Data From Graves' Disease Study of Batoclimab
    Sep 9 Roivant Provides Update on Graves’ Disease Development Program
    Sep 9 Immunovant Provides Update on Graves’ Disease Development Program
    Sep 5 Why Is Immunovant (IMVT) Up 13.8% Since Last Earnings Report?
    Sep 5 Immunovant to Host Graves’ Disease Program Update on September 9, 2024
    Sep 2 Are Investors Undervaluing Immunovant, Inc. (NASDAQ:IMVT) By 46%?
    See more IMVT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 45.58
    52 Week Low 19.5
    Average Volume 993,187
    200-Day Moving Average 32.50
    50-Day Moving Average 29.88
    20-Day Moving Average 30.90
    10-Day Moving Average 30.38
    Average True Range 1.40
    RSI (14) 43.18
    ADX 17.07
    +DI 20.09
    -DI 25.63
    Chandelier Exit (Long, 3 ATRs) 30.28
    Chandelier Exit (Short, 3 ATRs) 32.57
    Upper Bollinger Bands 33.90
    Lower Bollinger Band 27.91
    Percent B (%b) 0.17
    BandWidth 19.39
    MACD Line -0.21
    MACD Signal Line 0.18
    MACD Histogram -0.3912
    Fundamentals Value
    Market Cap 4.18 Billion
    Num Shares 145 Million
    EPS -1.96
    Price-to-Earnings (P/E) Ratio -14.74
    Price-to-Sales 0.00
    Price-to-Book 20.38
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 30.73
    Resistance 3 (R3) 30.79 30.25 30.43
    Resistance 2 (R2) 30.25 29.78 30.22 30.32
    Resistance 1 (R1) 29.57 29.49 29.30 29.51 30.22
    Pivot Point 29.03 29.03 28.89 29.00 29.03
    Support 1 (S1) 28.35 28.56 28.08 28.29 27.58
    Support 2 (S2) 27.81 28.27 27.78 27.48
    Support 3 (S3) 27.13 27.81 27.38
    Support 4 (S4) 27.07